Nothing Special   »   [go: up one dir, main page]

JPH10165774A - Permselective hollow yarn membrane - Google Patents

Permselective hollow yarn membrane

Info

Publication number
JPH10165774A
JPH10165774A JP32528096A JP32528096A JPH10165774A JP H10165774 A JPH10165774 A JP H10165774A JP 32528096 A JP32528096 A JP 32528096A JP 32528096 A JP32528096 A JP 32528096A JP H10165774 A JPH10165774 A JP H10165774A
Authority
JP
Japan
Prior art keywords
hollow fiber
membrane
albumin
fiber membrane
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP32528096A
Other languages
Japanese (ja)
Other versions
JP3295321B2 (en
Inventor
Shingo Emi
慎悟 江見
Koji Soga
宏治 曽我
Shoji Mizutani
昭治 水谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18175056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH10165774(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Ltd filed Critical Teijin Ltd
Priority to JP32528096A priority Critical patent/JP3295321B2/en
Publication of JPH10165774A publication Critical patent/JPH10165774A/en
Application granted granted Critical
Publication of JP3295321B2 publication Critical patent/JP3295321B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Artificial Filaments (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a permselective hollow yarn membrane enhancing efficiency for removing a harmful substance such as β2 -MB and preventing the outflow of a useful substance such as albumin in blood dialysis by respectively setting voids at a time of wetness and an albumin sieve coefficient after the one-hr perfusion of bovine serum to specific values. SOLUTION: In a permselective hollow yarn membrane composed of a cellulose derivative, it is desirable that the occupying ratio of pores in the vol., that is, void vol. of a membrane wall from an aspect of the permeability of a substance through the membrane wall is high in relation to the structure of the membrane wall and the void ratio is 75% or more, desirably, about 78% or more. The albumin sieve coefficient of this hollow yarn membrane measured after bovine serum is perfused for one hr is 0.04 or less, pref., about 0.02 or less and, though the permeability of water, a low molecular substance and a substance with a mol.wt. is good, the permeability of albumin with a mol.wt. of about 66,000 through the hollow yarn membrane is sufficiently prevented and this membrane has sharp fractionation characteristics between these mol.wts.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、選択透過性中空糸
膜に関するものである。更に詳しくは、特定の湿潤時の
空孔率、及び特定のアルブミン篩係数を有し、優れた分
離性能を呈する選択透過性を有するものであり、血液透
析、血液濾過透析等の血液処理に適し、特に中高分子量
領域の有害物質を除去するのに適した選択透過性中空糸
膜を提供するものである。
TECHNICAL FIELD The present invention relates to a selectively permeable hollow fiber membrane. More specifically, it has a specific wet porosity, and a specific albumin sieving coefficient, and has selective permeability exhibiting excellent separation performance, and is suitable for blood treatment such as hemodialysis and hemofiltration dialysis. In particular, the present invention provides a selectively permeable hollow fiber membrane suitable for removing harmful substances in a medium-high molecular weight region.

【0002】[0002]

【従来技術】選択透過性中空糸膜は、逆浸透や血液透析
等において従来より実用的に使用されてきている。特に
腎不全患者の血液を浄化するために、現在では中空糸型
血液透析器がよく使用されている。これは筐体の中に透
析膜、例えば、中空糸の膜を多数本収納し、その中空内
部に患者の血液を流し、外部、即ち中空糸間隙部に透析
液を流して、中空糸膜壁を介して透析することによっ
て、血液中の老廃物を除去し電解質濃度を是正するとと
もに、中空糸内外に圧力差を与えて限外濾過によって血
液中の余剰水分を除去するものである。更に、血液中か
ら血漿のみを分離し、あるいは、その血漿の中から特定
成分を除去して自己免疫疾患などを治療するために、中
空糸が使用されることもある。また最近になってタンパ
ク透過性血液透析やタンパク透過性血液濾過透析に中空
糸を用いることによって治療効果が得られることが確認
されるようになってきている。
2. Description of the Related Art Permselective hollow fiber membranes have been practically used in reverse osmosis and hemodialysis. In particular, hollow fiber hemodialyzers are often used at present for purifying blood of patients with renal failure. In this case, a dialysis membrane, for example, a large number of hollow fiber membranes, is housed in a housing, a patient's blood is allowed to flow inside the hollow, and a dialysate is allowed to flow outside, that is, a hollow fiber gap portion, and a hollow fiber membrane wall is formed. The dialysis removes wastes in the blood and corrects the electrolyte concentration, and applies a pressure difference between the inside and outside of the hollow fiber to remove excess water in the blood by ultrafiltration. Furthermore, hollow fibers are sometimes used to separate plasma alone from blood or to remove specific components from the plasma to treat autoimmune diseases and the like. Recently, it has been confirmed that a therapeutic effect can be obtained by using hollow fibers in protein-permeable hemodialysis or protein-permeable hemofiltration dialysis.

【0003】このように血液処理用の中空糸は目的に応
じて特定の物質を選択的に透過せしめなければならな
い。その性能は、中空糸の素材、ポロシテイ(孔の大き
さ、数など)、膜厚などによって決定される。
As described above, a hollow fiber for blood treatment must selectively allow a specific substance to permeate according to the purpose. The performance is determined by the material of the hollow fiber, the porosity (the size and number of holes), the film thickness, and the like.

【0004】ところで、近年、透析患者の長期合併症と
関連し、透析アミロイドシスの原因物質と考えられるβ
2-ミクログロブリン(β2-MG、分子量11,80
0)、掻痒感、高脂血症と関係すると考えられる副甲状
腺ホルモン(分子量約9,500)、貧血に関与する赤
芽球抑制因子、関節痛、骨痛に係わると考えられる分子
量2〜4万の物質など、比較的中高分子量領域の有害物
質の除去の必要性が叫ばれている。一方、人体に必須の
アルブミン(分子量66,000)の損失は極力避けな
ければならない。すなわち、分子量4〜5万以下の物質
の透過性に優れ、分子量6万以上の物質の阻止性のよい
分画分子量のシャープカット性の良好な選択透過性膜が
望まれている。
[0004] In recent years, β which is considered to be a causative substance of dialysis amyloidosis is associated with long-term complications of dialysis patients.
2- microglobulin (β 2 -MG, molecular weight 11,80
0), parathyroid hormone (molecular weight of about 9,500) considered to be associated with pruritus, hyperlipidemia, erythroblast inhibitory factor involved in anemia, molecular weight of 2 to 4 considered to be associated with arthralgia and bone pain The necessity of removing harmful substances in a relatively medium-high molecular weight region, such as thousands of substances, has been called for. On the other hand, loss of albumin (molecular weight: 66,000), which is essential for the human body, must be avoided as much as possible. That is, there is a demand for a permselective membrane having excellent permeability for substances having a molecular weight of 40,000 to 50,000 or less and good cutoff of the molecular weight of the fraction having good blocking properties for substances having a molecular weight of 60,000 or more.

【0005】しかるに、従来、ポリスルホンなどの合成
高分子では、例えば特公平2−18695号や特公平5
−54373号に見られるように、比較的上記要求を満
たしたものが得られているが、セルロース誘導体特にト
リアセテートでは、例えば特公昭58−24165号に
見られるように、中空糸を湿式紡糸するときの芯剤に流
動パラフィン、高級アルコール、イソプロピルミリステ
ートなど、トリアセテート紡糸原液に対し凝固性のない
ものを使用するために、紡糸原液におけるトリアセテー
トの濃度を高め、紡糸時の曳糸性を高くせざるを得な
い。また、紡糸原液をノズルから出糸後、中空糸外面か
ら凝固液で固化させるために、中空糸外面に緻密構造の
層が形成される。
[0005] However, conventionally, synthetic polymers such as polysulfone are disclosed in, for example, Japanese Patent Publication No.
As shown in JP-A-54373, those which relatively satisfy the above requirements have been obtained. However, in the case of cellulose derivatives, particularly triacetate, for example, as shown in JP-B-58-24165, when a hollow fiber is wet-spun. In order to use non-coagulable triacetate spinning solution, such as liquid paraffin, higher alcohol, isopropyl myristate, etc., as the core agent, the concentration of triacetate in the spinning solution should be increased to improve spinning during spinning. Not get. In addition, a layer having a dense structure is formed on the outer surface of the hollow fiber in order to solidify the spinning stock solution from the nozzle and then solidify the outer surface of the hollow fiber with the coagulating liquid.

【0006】これらの理由により、従来、セルロース誘
導体中空糸は、合成ポリマーの膜に比し、構造の緻密層
と多孔層の密度差が小さく、全体として均一層に近く、
物質の透過性能が十分とはいえなかった。そのために膜
の厚さを減少せしめ、透過性の向上を図ってきたが、十
分なものとはいえない。更に、膜構造の緻密層と多孔層
の密度差が不明確なために、透過物質の分画特性におい
ても、改良の余地のあるものであった。
[0006] For these reasons, conventionally, a cellulose derivative hollow fiber has a smaller difference in density between a dense layer and a porous layer in structure than a synthetic polymer membrane, and is close to a uniform layer as a whole.
The permeability of the substance was not sufficient. For this purpose, the thickness of the film has been reduced and the permeability has been improved, but this is not sufficient. Furthermore, since the density difference between the dense layer and the porous layer having a membrane structure is unclear, there is room for improvement in the fractionation characteristics of the permeated substance.

【0007】[0007]

【発明が解決しようとする課題】本発明は、このような
従来技術の問題点を解決することを目的とするものであ
って、セルロース誘導体のポリマーを使用して従来の合
成ポリマーの構造に近い粗密構造を与え、高い分子量分
画特性を付与することである。特に血液透析や血液濾過
透析においてβ2-MG等の中高分子量領域の有害物質の
除去とアルブミンなどの有用物質の流出阻止を高めるこ
とが可能な選択透過性中空糸膜を提供することを目的と
している。
SUMMARY OF THE INVENTION An object of the present invention is to solve such problems of the prior art, and to use a polymer of a cellulose derivative to approximate the structure of a conventional synthetic polymer. The purpose is to provide a dense and dense structure and to impart high molecular weight fractionation characteristics. In particular, it is an object of the present invention to provide a selectively permeable hollow fiber membrane capable of removing harmful substances in the medium-high molecular weight region such as β 2 -MG and preventing outflow of useful substances such as albumin in hemodialysis and hemofiltration dialysis. I have.

【0008】[0008]

【課題を解決するための手段】本発明者は、かかる目的
を達成するために鋭意研究した結果、特定の湿潤時の空
孔率及びアルブミンの篩係数を有する中空糸を用いた血
液浄化器が飛躍的に高められた分離性能を発揮すること
を見い出し、本発明に到達した。
Means for Solving the Problems The inventors of the present invention have made intensive studies to achieve the above object, and as a result, a blood purifier using a hollow fiber having a specific porosity when wet and a sieving coefficient of albumin has been developed. The present inventors have found that a dramatically improved separation performance is exhibited, and reached the present invention.

【0009】すなわち、本発明は、選択透過性を有する
中空糸において該中空糸膜の湿潤状態における空孔率が
75%以上であり、且つ牛血漿を1時間潅流した後のア
ルブミン篩係数(SC)が0.04以下であることを特
徴とする、実質的にセルロース誘導体からなる選択透過
性中空糸膜を提供するものである。
That is, according to the present invention, in a hollow fiber having selective permeability, the porosity of the hollow fiber membrane in a wet state is 75% or more, and the albumin sieving coefficient (SC) after perfusing bovine plasma for 1 hour. ) Is 0.04 or less, and provides a selectively permeable hollow fiber membrane substantially composed of a cellulose derivative.

【0010】[0010]

【発明の実施の形態】本発明における中空糸膜は、選択
透過性を有するものであり、その素材としては、セルロ
ース誘導体、特にアセチルセルロースであり、その中で
も一般的に使用されるものとしては、実質的にセルロー
スジアセテート、セルローストリアセテートからなる高
分子である。なお、実質的とは、このセルロース誘導体
の特性を損わない範囲で、他の高分子、添加物などを含
有してもよいことを意味する。
BEST MODE FOR CARRYING OUT THE INVENTION The hollow fiber membrane of the present invention has a selective permeability, and is made of a cellulose derivative, particularly acetylcellulose. It is a polymer consisting essentially of cellulose diacetate and cellulose triacetate. Note that “substantially” means that other polymers, additives, and the like may be contained as long as the properties of the cellulose derivative are not impaired.

【0011】本発明の中空糸膜の膜壁の構造に関して
は、膜壁を通しての物質の透過性の点からは、膜壁の体
積中の孔に占める割合、即ち空孔率が高いのが望まし
く、本発明にかかる中空糸膜では、空孔率は75%以上
であり、望ましくは78%以上である。
Regarding the structure of the membrane wall of the hollow fiber membrane of the present invention, it is desirable that the proportion of the pores in the volume of the membrane wall, that is, the porosity, is high from the viewpoint of the permeability of the substance through the membrane wall. In the hollow fiber membrane according to the present invention, the porosity is 75% or more, preferably 78% or more.

【0012】しかし、一般に空孔率が高くなると、分子
量の大きい分子が通過し易くなり、本発明の主たる目的
である血液透析においては、人体に必須なアルブミンの
篩係数は0.04以下であり、アルブミンより小さい分
子量の物質とアルブミンの透過性に選択性を付与するも
のである。
However, in general, when the porosity is high, molecules having a high molecular weight can easily pass therethrough. In hemodialysis, which is the main object of the present invention, the sieving coefficient of albumin, which is essential for the human body, is 0.04 or less. , A substance having a molecular weight smaller than albumin and imparting selectivity to the permeability of albumin.

【0013】一般にこのような膜は、均質な多孔構造の
ものでは実現が難しく、物質の分離透過特性と機械特性
を機能分担させるような、即ち、分離を規定する極薄緻
密層と、機械的に流体圧力に耐えられるが、物質の透過
抵抗には殆んど影響しない多孔層とを合せ持つような、
従来、合成高分子で実現されていた2層又は多層構造が
好ましい。特に、中空糸膜の内面を通して血液を処理す
る場合には、少くとも中空糸内面に緻密層があるのが望
ましい。内面に多孔層があると、その部分に血中蛋白が
付着したり、あるいは孔中に侵入したりして、物質透過
の阻害になる懸念がある。
In general, it is difficult to realize such a membrane with a uniform porous structure, and it is difficult to realize the separation and permeation characteristics and the mechanical properties of a material, that is, an ultrathin dense layer for defining the separation, Such as having a porous layer that can withstand fluid pressure but has little effect on the permeation resistance of a substance.
Conventionally, a two-layer or multilayer structure realized by a synthetic polymer is preferable. In particular, when blood is processed through the inner surface of the hollow fiber membrane, it is desirable that there is a dense layer at least on the inner surface of the hollow fiber. If there is a porous layer on the inner surface, there is a concern that blood proteins may adhere to that portion or penetrate into the pores, thereby impeding the permeation of substances.

【0014】本発明に係わる中空糸膜は、牛血漿を1時
間潅流した後に測定したアルブミン篩係数が0.04以
下であることを特徴としている。好ましくは0.02以
下であり、水、低分子物質及び分子量10,000〜2
0,000の物質透過性が良好であるのに拘わらず、分
子量が約66,000のアルブミンの中空糸膜を通じて
の透過性は十分に阻止されているものであり、これらの
分子量の間にシャープな分画特性を有している。
The hollow fiber membrane according to the present invention is characterized in that the albumin sieving coefficient measured after perfusing bovine plasma for one hour is 0.04 or less. It is preferably 0.02 or less, and water, a low molecular weight substance and a molecular weight of 10,000-2.
Despite the good material permeability of 000, the permeability of albumin with a molecular weight of about 66,000 through the hollow fiber membrane is well inhibited and there is a sharp difference between these molecular weights. It has excellent fractionation characteristics.

【0015】中空糸膜の膜厚は、一般に物質の透過性か
らみれば薄いのが望ましいが、本発明に係わるような空
孔率の高いものでは、機械的強度の点より30μm以上
が好ましい。なお、中空糸膜の内径は100〜300μ
m、更には150〜250μmが好ましい。
Generally, the thickness of the hollow fiber membrane is desirably small in view of the permeability of the substance. However, in the case of the high porosity according to the present invention, the thickness is preferably 30 μm or more from the viewpoint of mechanical strength. The inner diameter of the hollow fiber membrane is 100 to 300 μm.
m, more preferably 150 to 250 μm.

【0016】このように本発明の中空糸膜は、血液透析
器や血液濾過透析に使用した場合に、β2-MGなどの中
高分子量の領域の有害物質の除去性能が高く、かつ低分
子量領域の有害物質の除去性能も優れている上に、人体
に有益なアルブミンの損失量が少ないという選択透過性
に優れたものである。
As described above, when the hollow fiber membrane of the present invention is used in a hemodialyzer or hemofiltration dialysis, it has a high ability to remove harmful substances in a medium-high molecular weight region such as β 2 -MG and has a low molecular weight region. In addition to the excellent performance of removing harmful substances, the selective permeation of albumin, which is beneficial to the human body, is small.

【0017】かかる本発明の中空糸膜の製造方法は特に
限定されるものではないが、望ましくはセルロース誘導
体を有機溶剤に溶解した紡糸原液を、芯剤として水溶液
を用いて、チューブインオリフィス状ノズルより吐出さ
せ、気体中を通過後、水溶性凝固液中に通し固化させる
方式が採用される。
Although the method for producing the hollow fiber membrane of the present invention is not particularly limited, a tube-in-orifice-shaped nozzle is preferably prepared by using an undiluted spinning solution obtained by dissolving a cellulose derivative in an organic solvent and using an aqueous solution as a core agent. A method is adopted in which the liquid is discharged more, passes through a gas, and then passes through a water-soluble coagulating liquid and solidifies.

【0018】尚、本発明に係る中空糸膜は、一般に高圧
蒸気滅菌が可能であり、高圧蒸気滅菌後のものも含まれ
る。
The hollow fiber membrane according to the present invention can be generally subjected to high-pressure steam sterilization, and includes those after high-pressure steam sterilization.

【0019】高圧蒸気滅菌により空孔率、アルブミンの
篩係数は多少低下するので、滅菌前に各々の値を高めに
設定しておく必要がある。
Since the porosity and the sieving coefficient of albumin are somewhat reduced by high-pressure steam sterilization, it is necessary to set each value to a high value before sterilization.

【0020】[0020]

【実施例】以下本発明について実施例をあげて更に具体
的に説明するが、本発明は、これらの実施例によって何
ら限定されるものではない。
EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.

【0021】[実施例1〜4]セルローストリアセテー
ト13部とトリエチレングリコール20部を、ジメチル
スルホオキシド67部に均一溶解したものを紡糸原液と
して、チューブインオリフィス型ノズルより、ジメチル
スルホオキシドの水溶液を芯剤として、空気中に吐出さ
せた後、凝固液の中に導いて固化させ、水洗、グリセリ
ン付着処理後、捲取った。得られた中空糸膜を乾燥後束
状にして、円管状の容器内に挿入充填して、両端をポリ
ウレタンで接着固定し、有効面積が約1.5m2 の血液
透析器を作成し、in vitroでの水透過性能(限
外濾過率、UFR)とデキストラン10,000の総括
物質移動係数(K0 )及び牛血漿を用いたアルブミンの
篩係数(SC)を測定した。
[Examples 1 to 4] A solution prepared by uniformly dissolving 13 parts of cellulose triacetate and 20 parts of triethylene glycol in 67 parts of dimethyl sulfoxide was used as a spinning solution, and an aqueous solution of dimethyl sulfoxide was supplied through a tube-in orifice type nozzle. After being discharged into the air as a core agent, it was guided into a coagulating liquid to be solidified, washed with water, glycerin-adhering treatment, and then wound up. The obtained hollow fiber membranes are dried, bundled, inserted and filled in a cylindrical container, and both ends are adhered and fixed with polyurethane to prepare a hemodialyzer having an effective area of about 1.5 m 2. The water permeability in vitro (ultrafiltration, UFR), the overall mass transfer coefficient (K 0 ) of dextran 10,000 and the sieving coefficient (SC) of albumin using bovine plasma were measured.

【0022】尚、評価項目の測定は、以下の方法で行っ
た。UFRの測定方法は、日本透析医学会学術委員会の
「血液浄化器」評価基準(案)(1994.5.10 )の「I.水
系におけるインビトロ性能評価、3.限外濾過、」に記載
の方法による。
The evaluation items were measured by the following methods. The method for measuring UFR is described in "I. In vitro performance evaluation in water system, 3. Ultrafiltration" in "Chemical Purifier" Evaluation Criteria (Draft) of the Scientific Committee of the Japanese Society for Dialysis Therapy (May 10, 1994). by.

【0023】デキストラン10,000の総括物質移動
係数K0 の測定方法は、円筒状容器に中空糸束を充填し
た上記1.5m2 の有効膜表面積の血液透析器に、37
℃において血液側すなわち中空部側に0.1重量%のデ
キストラン10,000の水溶液を200ml/分で流
し、透析液側すなわち中空糸間隙部側に水を500ml
/分で流した場合の血液側の流出液中の濃度を測定する
ことによって、下記式によりK0 が得られる。サンプリ
ング液中のデキストラン濃度は、例えばアンスロン―硫
酸法により測定する。
The method of measuring the overall mass transfer coefficient K 0 of dextran 10,000 is as follows, using a hemodialyzer having an effective membrane surface area of 1.5 m 2 filled with hollow fiber bundles in a cylindrical container.
At 0 ° C., a 0.1% by weight aqueous solution of 10,000 dextran was flowed at 200 ml / min to the blood side, that is, the hollow side, and 500 ml of water was flown to the dialysate side, that is, the hollow fiber gap side.
By measuring the concentration in the effluent on the blood side at a flow rate of / min, K 0 is obtained by the following equation. The dextran concentration in the sampling solution is measured by, for example, an anthrone-sulfuric acid method.

【0024】[0024]

【数1】 (Equation 1)

【0025】QB :血液側の流量[ml/sec] QD :透析液側の流量[ml/sec] DA :デキストラン10,000のダイアリザンスで、
その測定法は日本透析医学会学術委員会in vitr
o評価ワーキンググループの評価法に基づく。 A :中空糸膜有効膜面積[cm2 ]:中空糸膜の湿潤
状態での内径基準の膜面積である。
Q B : flow rate on the blood side [ml / sec] Q D : flow rate on the dialysate side [ml / sec] DA: dextran 10,000 dialysance
The measurement method is in vitro by the Japanese Dialysis Medical Association Scientific Committee
o Based on the evaluation working group evaluation method. A: Effective membrane area of hollow fiber membrane [cm 2 ]: Membrane area based on the inner diameter of the hollow fiber membrane in a wet state.

【0026】アルブミンの篩係数(SC)の測定方法
は、日本透析医学会学術委員会の血液浄化器の牛血漿の
in vitro評価プロトコールと機能分類
(案)('94.11.12 )による。アルブミン濃度の測定
は、A/G B−テストワコー(和光純薬(株))によ
り行った。
The method of measuring the sieving coefficient (SC) of albumin is based on the in vitro evaluation protocol and functional classification (draft) ('94 .11.12) of bovine plasma in blood purifiers by the Scientific Committee of the Japanese Society for Dialysis Therapy. The measurement of albumin concentration was performed by A / GB-Test Wako (Wako Pure Chemical Industries, Ltd.).

【0027】[比較例1、2]セルローストリアセテー
ト25部とトリエチレングリコール20部を、N−メチ
ルピロリドン55部に均一溶解したものを紡糸原液と
し、実施例1〜4と同様の方法で中空糸膜を得、有効面
積約1.5m2 の血液透析器を作成した。また、実施例
1〜4と同様の方法で評価項目を測定した。
[Comparative Examples 1 and 2] A hollow fiber was prepared by uniformly dissolving 25 parts of cellulose triacetate and 20 parts of triethylene glycol in 55 parts of N-methylpyrrolidone as a stock solution for spinning. A membrane was obtained, and a hemodialyzer having an effective area of about 1.5 m 2 was prepared. Evaluation items were measured in the same manner as in Examples 1 to 4.

【0028】[比較例3、4]セルローストリアセテー
ト20部とトリエチレングリコール20部を、N−メチ
ルピロリドン60部に均一溶解したものを紡糸原液と
し、流動パラフィンを芯剤として実施例1〜4と同様の
方法で中空糸膜を得、有効面積約1.5m2 の血液透析
器に組み立てた。芯剤の流動パラフィンを十分に洗浄除
去した後、実施例1〜4と同様の方法で評価項目を測定
した。その結果を表1に示す。
[Comparative Examples 3 and 4] A solution prepared by uniformly dissolving 20 parts of cellulose triacetate and 20 parts of triethylene glycol in 60 parts of N-methylpyrrolidone was used as a stock solution for spinning, and liquid paraffin was used as a core agent. A hollow fiber membrane was obtained in the same manner and assembled into a hemodialyzer having an effective area of about 1.5 m 2 . After sufficiently washing and removing the liquid paraffin as the core agent, evaluation items were measured in the same manner as in Examples 1 to 4. Table 1 shows the results.

【0029】[0029]

【表1】 [Table 1]

【0030】表1は実施例1〜4及び比較例1〜4の紡
糸条件と、in vitroの特性値及び評価項目を示
したものである。
Table 1 shows spinning conditions of Examples 1 to 4 and Comparative Examples 1 to 4, characteristic values in vitro and evaluation items.

【0031】本発明の中空糸は、除水性能、デキストラ
ン10,000の透過性能が高く、且つアルブミンの透
過が抑えられた分子量分画特性の良好なものになってい
る。
The hollow fiber of the present invention has high water-removing performance, high permeation performance of dextran 10,000, and good molecular weight fractionation characteristics in which albumin permeation is suppressed.

【0032】[0032]

【発明の効果】本発明の中空糸膜は、その集束体を用い
て血液浄化器を組み立てた場合、中高分子量領域の有害
物質の除去性能が高く、アルブミンの透析液中への漏出
量が少ないという優れた効果を奏するものである。
According to the hollow fiber membrane of the present invention, when a blood purifier is assembled by using the bundle, the performance of removing harmful substances in the medium high molecular weight region is high and the amount of albumin leaking into the dialysate is small. This is an excellent effect.

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 選択透過性を有する中空糸膜において、
該中空糸膜の湿潤状態における空孔率が75%以上であ
り、かつ牛血漿を1時間潅流した後のアルブミン篩係数
(SC)が0.04以下であることを特徴とする実質的
にセルロース誘導体からなる選択透過性中空糸膜。
1. A hollow fiber membrane having permselectivity,
Substantially cellulose, wherein the porosity of the hollow fiber membrane in a wet state is 75% or more, and the albumin sieving coefficient (SC) after perfusing bovine plasma for 1 hour is 0.04 or less. A permselective hollow fiber membrane made of a derivative.
【請求項2】 該選択透過性中空糸膜が、少なくとも内
面に緻密層を有する請求項1に記載の選択透過性中空糸
膜。
2. The permselective hollow fiber membrane according to claim 1, wherein the permselective hollow fiber membrane has a dense layer at least on an inner surface.
【請求項3】 該選択透過性中空糸膜が、実質的にセル
ローストリアセテートからなる請求項1又は2に記載の
選択透過性中空糸膜。
3. The permselective hollow fiber membrane according to claim 1, wherein the permselective hollow fiber membrane substantially consists of cellulose triacetate.
【請求項4】 該選択透過性中空糸膜が、高圧蒸気滅菌
したものからなる請求項1〜3のいずれかに記載の選択
透過性中空糸膜。
4. The permselective hollow fiber membrane according to claim 1, wherein said permselective hollow fiber membrane is obtained by high-pressure steam sterilization.
JP32528096A 1996-12-05 1996-12-05 Permselective hollow fiber membrane Expired - Fee Related JP3295321B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP32528096A JP3295321B2 (en) 1996-12-05 1996-12-05 Permselective hollow fiber membrane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32528096A JP3295321B2 (en) 1996-12-05 1996-12-05 Permselective hollow fiber membrane

Publications (2)

Publication Number Publication Date
JPH10165774A true JPH10165774A (en) 1998-06-23
JP3295321B2 JP3295321B2 (en) 2002-06-24

Family

ID=18175056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP32528096A Expired - Fee Related JP3295321B2 (en) 1996-12-05 1996-12-05 Permselective hollow fiber membrane

Country Status (1)

Country Link
JP (1) JP3295321B2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027447A1 (en) * 1998-11-09 2000-05-18 Asahi Medical Co., Ltd. Blood purifying apparatus
JP2001038154A (en) * 1999-08-03 2001-02-13 Kuraray Co Ltd Separation membrane of blood plasma
JP2001038169A (en) * 1999-08-03 2001-02-13 Kuraray Co Ltd Blood plasma component separation membrane
WO2007102528A1 (en) 2006-03-09 2007-09-13 Toyo Boseki Kabushiki Kaisha Hollow fiber membrane with excellent performance stability and blood purifier and method for producing hollow fiber membrane
JP2008284186A (en) * 2007-05-18 2008-11-27 Toyobo Co Ltd Porous hollow-fiber membrane with superior stable permeability

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027447A1 (en) * 1998-11-09 2000-05-18 Asahi Medical Co., Ltd. Blood purifying apparatus
US6632359B1 (en) 1998-11-09 2003-10-14 Asahi Medical Co., Ltd. Blood purifying apparatus
JP2001038154A (en) * 1999-08-03 2001-02-13 Kuraray Co Ltd Separation membrane of blood plasma
JP2001038169A (en) * 1999-08-03 2001-02-13 Kuraray Co Ltd Blood plasma component separation membrane
WO2007102528A1 (en) 2006-03-09 2007-09-13 Toyo Boseki Kabushiki Kaisha Hollow fiber membrane with excellent performance stability and blood purifier and method for producing hollow fiber membrane
JP2008284186A (en) * 2007-05-18 2008-11-27 Toyobo Co Ltd Porous hollow-fiber membrane with superior stable permeability

Also Published As

Publication number Publication date
JP3295321B2 (en) 2002-06-24

Similar Documents

Publication Publication Date Title
US4874522A (en) Polysulfone hollow fiber membrane and process for making the same
US6605218B2 (en) Dialyzers for blood treatment and processes for production thereof
CS226188B2 (en) Dialysing diaphragm in the form of flat foil,tubular foil or hollow filament made of cellulose regenerated by using cuoxam process
WO1997034687A1 (en) Hollow yarn membrane used for blood purification and blood purifier
US6013182A (en) Selectively permeable hollow fiber membrane and process for producing same
JPH10108907A (en) Membrane for hemocatharsis, its preparation and module for hemocatharsis
JP2792556B2 (en) Blood purification module, blood purification membrane and method for producing the same
JP2000140589A (en) Porous polysulfone film
JP3295321B2 (en) Permselective hollow fiber membrane
JPH10263375A (en) Selective permeable hollow fiber membrane
JP3253861B2 (en) Permselective hollow fiber membrane
JP2703266B2 (en) Polysulfone hollow fiber membrane and method for producing the same
JP3253867B2 (en) Permselective hollow fiber membrane
JP4029312B2 (en) Permselective hollow fiber membrane
JPH09308685A (en) Hollow fiber membrane for blood purification and blood purifying device
JP3253885B2 (en) Permselective hollow fiber membrane
JP3424810B2 (en) High performance blood purification membrane
JPH0970431A (en) Production of polysulfone hollow fiber type artificial kidney and artificial kidney
JP3345260B2 (en) Permselective hollow fiber membrane
JP3236233B2 (en) Method for producing selectively permeable hollow fiber membrane
JP3651121B2 (en) Permselective separation membrane
JP4003982B2 (en) Polysulfone-based selectively permeable separation membrane
JP3295314B2 (en) Permselective hollow fiber membrane
JP2000107577A (en) Production of permselective hollow fiber membranes
JP2812890B2 (en) Blood purifier

Legal Events

Date Code Title Description
FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080405

Year of fee payment: 6

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090405

Year of fee payment: 7

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 8

Free format text: PAYMENT UNTIL: 20100405

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 8

Free format text: PAYMENT UNTIL: 20100405

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110405

Year of fee payment: 9

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120405

Year of fee payment: 10

LAPS Cancellation because of no payment of annual fees